By Aaron Krol
Awarded in September of this year, the grant will culminate in a 300-person trial of the fine-tuned test before UC Davis prepares it for clinical release. PacBio is closely involved in the project, which could establish a unique position for the company in clinical use at a time when the sequencing industry is scrambling to enter the clinical market. Illumina, the world’s largest sequencing company, recently received FDA approval for a cystic fibrosis diagnostic, a landmark in medical genetics. QIAGEN, a multibillion-dollar diagnostics company, is preparing to release the new GeneReader instrument specifically for clinical use.
PacBio is smaller than either of these companies, but its SMRT sequencers are the only instruments that can access fragile X mutations. “We are right now in the business of facilitating sequencing that can’t be done using other techniques,” Turner, who is also principal investigator for the NIH grant, told Bio-IT World. “The longest read length of any technology other than PacBio is about one thousand bases, so they’re far short of being able to cover [the range of FMR1 mutations].”
Two aspects of SMRT technology – the acronym stands for single molecule, real time – give PacBio the coverage needed to delve into the black boxes of the genome. The first is a DNA polymerase engineered from the f29 bacteriophage. Bacteriophages, viruses that invade bacteria and replicate inside their hosts, use polymerases to copy their genetic sequences. The f29 phage is remarkable for replicating its entire, nearly 20,000-base genome in a single step, using just one enzyme. Armed with this highly accurate, long-reading polymerase, a SMRT sequencer can chew through thousands of bases using just one enzyme and one molecule of sample DNA. (Go to IHUB for full story & link)
Michael (Mike) Hunkapiller has been an early investor in PACB as part of Alloy Ventures before becoming President of PACB. He is a veteran in sequencing business and I trust him.
I trust him but I do survey the market for emerging technology that might disrupt the market. Nano-pore has great potential but they have serious challenges due to their 3 base detection issues. PACB has virtually no competition and PACB is gold standard in sequencing business. PACB has been growing fast but major catalyst will be small sequencer to compete with Illumina and enter in diagnostic market. I think it coming soon based on Roche and PACB collaboration.
Right board, wrong basher, I meant nimuma, drd369 is a basher on another message board.
While planning the next new generation of machines, PE Biosystems' president, Michael W. Hunkapiller, calculated that it would be possible for their own private industry to decode the human genome before the academic consortium could complete it, by using the resources of a single, industrial-scale center, even though it would require starting from scratch. It was a bold prediction, given that the consortium target date set by Dr. Watson back in 1990 had been the forward year of 2005, only seven years away, and with the consortium already half the way to the completion target date.
Also, it meant that Dr. Hunkapiller's idea would require competing against his own customers, to all of whom Applied Biosystems sold its sequencing machines and their chemical reagents. However, he calculated that it would also mean doubling the market for that equipment.
Hunkapiller brought in Dr. J. Craig Venter to direct the project. Tony White, president of the Perkin-Elmer Corporation backed Hunkapiller on the venture. They organized the new company to accomplish the task. In May 1998, Celera Genomics was formed, to rapidly accelerate the human DNA sequencing process. Dr. Venter boldly declared to the media that he would complete the genome decoding by 2001. That bold announcement prompted the academic consortium to accelerate their own deadline by a couple years, to 2003.
Why are you being so helpful to us poor shareholders?
You are truly a great person going out on the limb for us.
You have every right to say what you want and unfortunately there may be some newbie shareholder who will get confused with all your help.
You obviously have plenty of free time to keep posting .
My opinion is that if you want to get info is to do ones own research and not bank on these message boards...They can take away as well as give confidence at the right or wrong times.
PacBio, the UK’s Sanger Institute and Public Health England will analyse the genomes of 3,000 bacterial pathogens.
( "PacBio’s 3rd generation SMRT sequencing technology achieves the longest read lengths and highest consensus accuracy in the industry. Because the technology can directly detect base modifications, the epigenomes for bacteria can also be obtained with no additional data acquisition, providing unprecedented insight into the role of DNA methylation in bacterial pathogenicity.")!! (IHUB for full story)
Check your homework. He has never been a CEO before PACBIO. He was the general manager and president of applied biosystem, after working at ABI as a scientist for many many years. He was a figurehead because his accomplishment as a Scientist. No offense to the smart science people, but they are good at research, not running business!
C'mon nimuma. don't dance away from what you said.......you said he has never had any CEO experience, that he is a "rookie" in his current position, it had NOTHING to do with him buying the stock.
By the way.....what did you think of his very IMPRESSIVE background that you FINALLY found out about on Wiki ?
What does it feel like to FINALLY be out of the dark.......ENLIGHTENED !
Refreshing ain't it ?
Are you kidding me? A CEO uses his life savings to pump his own stock? Isn't it rookie a what?
Haha,,, This is what nimuma thinks of Dr.Michael W. Hunkapiller........"He has never been the CEO guy, in this level he is just a rookie."
Yeah nimuma.....Mr. Hunkapiller is a "rookie".
I hit it on the head with you.......you have NO CLUE of his background, oh I'm sure you do now that I suggested you do a search on Applied Biosystems.
But all along you have been TOTALLY clueless on the Dr.
And for a guy that berates everyone else.......it was so EASY to look.....BEFORE you flapped your trap!
Well nimuma, there's the cheap seats, and the premium up front seats, and then there's you out in the parking lot trying to guess every move according to the noise you hear. While Mr. Hunkapiller is right down there calling the shots, so he has a pretty good idea what he's doing with his money.
Have you ever taken the time to look into his background ?
Do a search on Applied Biosystems.....read the Wikipedia on that one, about three quarters down you will see the magnitude of what Pacific Biosystems has in Dr.Michael W. Hunkapiller.
I challenge anybody to find another company of this size and stature with someone at the helm of Mr. Hunkapiller's capacity.
Any patient investor in PACB is going to be very handsomely rewarded.
PACB Will not go undiscovered for very much longer.
It's in that process of being discovered right now.
Separately, analysts at Maxim Group raised their price target on shares of Pacific Biosciences of California from $4.00 to $8.00 in a research note to investors on Thursday, September 26th. They now have a “buy” rating on the stock.
(same link as last).
(Posted by Joseph Griffin on Dec 13th, 2013 Pacific Biosciences of California (NASDAQ:PACB) CEO Michael Hunkapiller purchased 100,000 shares of Pacific Biosciences of California stock on the open market in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $4.13 per share, with a total value of $413,000.00. Following the acquisition, the chief executive officer now directly owns 1,800,000 shares in the company, valued at approximately $7,434,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. on IHUB.
You have alot room here to elaborate. What are they saying. You want people to buy then tell us what they are saying.
You actually think he is just bailing out the stock ?
Does it sound logical to you that he would put that kind of capital of his OWN into PACB stock.......with no expected profit on that capital?
He's just doing it to comfort us ?
They are called insiders for a reason.
koloric......Put these two words together....and add the dot (c)om. This is the ridiculous way we have to post stuff now because Yahoo won't even let you write out sites let alone the link. Even when I write it out they still catch it sometimes and won't post the message.
Put these words together insider cow. (c)om.
Then punch in whatever stock you want. And even at the top of the page you can select the 'latest buys', and the 'latest sells' and it will give a bunch of other stocks also.